Moderna
Moderna was founded in 2010 by Derrick Rossi, Timothy A. Springer, Robert S. Langer, Kenneth R. Chien, and Noubar Afeyan. Moderna is headquartered in Cambridge, Massachusetts. The company focuses on infectious, cardiovascular, rare, and autoimmune diseases. It also focuses on Immuno-Oncology and mRNA vaccines.
Moderna employs (as of 2022) over 2,500 people, and is traded on NASDAQ.
Location: Massachusetts
Industry: Pharmaceutical and biotechnology
Sector: Healthcare
CEO: Stéphane Bancel
Valuation: $56 billion
Latest Moderna News and Updates
Healthcare Moderna Is Suing Pfizer and BioNTech Over Patent Misuse
Moderna and Pfizer produced vaccines in record time to help people get inoculated against COVID-19. Why is Moderna suing Pfizer? Here's what we know.Healthcare Explainer: Pfizer vs. Moderna COVID-19 Vaccines for Kids Under 5
Pfizer and Moderna both offer a COVID-19 vaccine for kids under five. Now, the FDA has approved both vaccines for children over six months of age.Healthcare Children Under 5 May Soon Be Eligible for Moderna COVID-19 Vaccine
Moderna has requested approval from the FDA to issue its COVID-19 vaccine for emergency use in children between the ages of 6 months and 5 years old.Company & Industry Overviews Moderna CEO Dumps Some MRNA Stocks in Planned Sell-Off
Moderna CEO Stéphane Bancel has proceeded with a planned sell-off and dumped about $3.6 million in MRNA stock. What does the sell-off mean?Healthcare Pfizer's Omicron Vaccine Should Be Available in March—Too Late?
Pfizer and Moderna are both working on a vaccine for the omicron variant of the COVID-19 virus. When will the vaccines be available? Will they be too late?News Which Vaccines Are Effective Against Omicron? Pfizer and Moderna
As the omicron variant of the COVID-19 virus spreads across globe, people want to know more about the vaccines. Which vaccines are effective against omicron?Healthcare Is It Time to Sell Moderna (MRNA) Stock and Book Profits?
On Nov. 5, Moderna stock fell 17 percent after a disappointing quarterly report. Is MRNA stock a buy or sell now based on its forecast?Healthcare When Will the Moderna Booster Be Available and Who Is Eligible?
When will the Moderna booster be available and who's eligible? Will people be able to mix and match COVID-19 vaccines?News Will the FDA Approve the Moderna COVID-19 Booster This Week?
Some people have gotten the Pfizer booster shot for the COVID-19 vaccine. When will Moderna's booster get FDA approval?News When Will Moderna's COVID-19 Vaccine Be Approved for Kids?
Moderna submitted a request in June for emergency use authorization of its two-shot COVID-19 vaccine for children aged 12–17. The FDA hasn’t given its approval yet.Healthcare When Will the FDA Fully Approve Moderna's COVID-19 Vaccine?
Investors want to know when the FDA will fully approve Moderna’s COVID-19 vaccine. FDA approval could fuel sales. Here's what investors can expect.Healthcare Moderna Has Not Got FDA Approval Yet, but Might Get It Soon
Pfizer-BioNTech vaccine became the first vaccine to be fully approved for COVID-19 by the FDA. Moderna’s vaccine is still awaiting FDA approval, but why?Healthcare Moderna Stock Falls, Could Go Back Up Amid Pumping From WallStreetbets
Moderna stock has come off its highs. Why is the stock falling and will it go back up on pumping from Reddit forum WallStreetBets?Healthcare Moderna Stock (MRNA) Could Keep Delivering Value for Years
Moderna stock has tripled this year. After its price surge, investors want to know Moderna's (MRNA) stock forecast for 2025. Does it look promising?Healthcare Did Moderna CEO Stéphane Bancel Take the Vaccine Himself?
Making a vaccine is one thing. Did the CEO of Moderna take the vaccine himself?Healthcare Who Owns Moderna?
Moderna, a biopharmaceutical company, has a coronavirus vaccine with initial trial results that show 94.5 percent effectiveness.Healthcare Moderna Stock Soars, COVID-19 Vaccine Looks Promising
Moderna (NASDAQ:MRNA) stock surged 16% in after-market trading hours on Tuesday following news of positive results related to its COVID-19 vaccine.